Physician profile
Daniel R Jasper
NPI 1730292509
$5,018.68
in general payments reported to CMS, 2019-2025
42 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $381 · 2021: $700 · 2022: $576 · 2023: $875 · 2024: $927 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,023 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,023.24 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.41 | 2020-2025 | |
| Lilly USA, LLC | $710.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $393.79 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $368.66 | 2020-2025 | |
| Novo Nordisk INC | $276.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $185.00 | 2019-2025 | Evenity, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.08 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.53 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Sumitomo Pharma America, INC. | $150.56 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $103.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $100.68 | 2019-2021 | |
| Amarin Pharma, INC. | $100.23 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.24 | 2024-2025 | Caplyta |
| Currax Pharmaceuticals LLC | $94.67 | 2019-2025 | Contrave, Nexletol |
| Janssen Pharmaceuticals, INC | $74.59 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.